WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 2 fonti

FDA warns Genzyme's Irish site over quality questions

FDA warning letter cites Genzyme's Waterford, Ireland site for data integrity failures and improperly canceled deviations following a January inspection.

Raccontata daendpoints.newsfiercepharma.com

Confronto fonti

2 prospettive sulla stessa storia
AI · summaries
endpoints.newsStai leggendo7 h fa

FDA warns Genzyme's Irish site over quality questions

FDA warning letter cites Genzyme's Waterford, Ireland site for data integrity failures and improperly canceled deviations following a January inspection.

originale
fiercepharma.com7 h fa

Sanofi unit in Ireland chided by FDA over manufacturing flubs linked to Altuviiio

After a site visit by FDA inspectors yielded a Form 483 for Genzyme Ireland in early 2026, the Sanofi subsidiary is facing further reprimand from the U.S. regulator.  | After a site visit by FDA inspectors yielded a…

Leggi questa versione → originale

Timeline cronologica

  1. mercoledì 1 luglio 2026·endpoints.news

    FDA warns Genzyme's Irish site over quality questions

    FDA warning letter cites Genzyme's Waterford, Ireland site for data integrity failures and improperly canceled deviations following a January inspection.

  2. mercoledì 1 luglio 2026·fiercepharma.com

    Sanofi unit in Ireland chided by FDA over manufacturing flubs linked to Altuviiio

    After a site visit by FDA inspectors yielded a Form 483 for Genzyme Ireland in early 2026, the Sanofi subsidiary is facing further reprimand from the U.S. regulator.  | After a…